Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US Hikma (HIK) announced on December 8, 2025 the U.S. launch of TYZAVAN™ (vancomycin injection, USP), a ready-to-use vancomycin premix with room-temperature stability.Key product features: FDA-approved for adults and pediatric patients (1 month+); available in seven strengths (0.5g–2g); 16-month shelf life at room temperature; supplied in pre-filled aseptic bags and compatible with automated dispensing cabinets.The product eliminates on-site compounding, aims to speed sepsis treatment, and is approved for marketing only in the United States.

#HIK #HKMPY Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US

www.stocktitan.net/news/HIK/hikma-launches-...

FDA Approval: Hikma's New Sepsis Drug TYZAVAN Cuts Critical Treatment Time by Eliminating Preparation Steps First ready-to-infuse vancomycin targets $200M market, eliminating preparation time in critical sepsis treatment. See how this breakthrough impacts patient care.

#HKMPY #HIK Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US

www.stocktitan.net/news/HKMPY/hikma-receive...

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines Hikma Pharmaceuticals (OTC:HKMPY) has announced a significant $1 billion investment to expand its US manufacturing and R&D capabilities by 2030. The initiative, dubbed "America Leans on Hikma," builds upon the company's 34-year presence in the US market and aims to enhance domestic production of essential generic medicines.The company currently operates facilities in Columbus and Cleveland, Ohio, and Cherry Hill and Dayton, New Jersey. Hikma has invested over $4 billion in the past 15 years and has the capacity to produce more than 12 billion finished doses annually. As a top three US supplier of sterile injectable medicines, Hikma maintains a portfolio of over 800 medicines, including more than 180 injectable products.

#HKMPY #HIK Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

www.stocktitan.net/news/HKMPY/hikma-pharmac...

Hikma acquires Novugen's FDA-approved ANDA for trametinib Hikma Pharmaceuticals has acquired the FDA-approved ANDA for trametinib tablets from Novugen, securing 180 days of US generic market sales exclusivity. The agreement positions Hikma to handle US sales and marketing while Novugen manages manufacturing and supply.Trametinib, an oral kinase inhibitor for cancer treatment, generated approximately $436 million in US sales under the brand name Mekinist® in the 12 months ending December 2024. This strategic acquisition strengthens Hikma's generics portfolio in oncology and expands its pipeline of essential medicines.The partnership aims to increase access to cost-efficient cancer treatments in the US market, where Hikma maintains a strong presence in complex generic technologies, including being the largest supplier by volume of nasal sprays.

#HKMPY #HIK Hikma acquires Novugen's FDA-approved ANDA for trametinib

www.stocktitan.net/news/HKMPY/hikma-acquire...

Hikma Partners with Emergent BioSolutions for KLOXXADO® Opioid Overdose Treatment Distribution Hikma Pharmaceuticals announces exclusive 6-year partnership with Emergent BioSolutions for KLOXXADO® nasal spray distribution in North America, expanding access to overdose treatment.

#HKMPY #HIK Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg

www.stocktitan.net/news/HKMPY/hikma-announc...